Literature DB >> 26136885

Study of the association between CD28/CTLA-4 expression and disease activity in juvenile idiopathic arthritis.

Lei Zhang1, Hui Liang1, Hui Guan1, Hualin Liu1.   

Abstract

The aim of the present study was to investigate the immune function of children with juvenile idiopathic arthritis (JIA). Flow cytometry and three-color direct immunofluorescence were used to examine cluster of differentiation (CD)3+ T-lymphocyte subsets and CD28/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in whole blood (using the no-wash method) from 36 children with JIA and 39 healthy children. During the active phase of JIA, CD28 expression on CD4+ T cells in children with JIA was significantly reduced; thus, CD4+CD28- T-cell frequency increased, suggesting that CD4+ T-cell and CD4+CD28- T-cell apoptosis was inhibited in patients with JIA. The continued survival of these immune-active T lymphocytes may promote the occurrence and development of JIA. CTLA-4 expression levels on CD4+ and CD8+ T cells in children with JIA during the active phase were significantly higher than those in normal controls. As the majority of CD4+ T cells in patients with JIA are CD28-, they cannot be inactivated by the interaction between CTLA-4 and B7, leading to continuously high levels of CTLA-4 expression on the surface of CD4+ T cells without functional effect. Hence, T lymphocytes are continuously kept in a highly activated state that is difficult to stop. During the resting phase, the CD4+ and CD8+ T-cell counts in children with JIA were similar to normal, and CD28 expression was also normal. This suggests that the frequency of CD4+CD28- T cells can be used as an indicator of the active phase of JIA. CTLA-4 expression on the surface of T cells in children with JIA during the resting phase was also similar to that in normal controls, suggesting that abnormal lymphocyte activation plays an important role in the active phase of JIA.

Entities:  

Keywords:  cluster of differentiation 28; costimulatory molecules; cytotoxic T lymphocyte-associated protein 4; juvenile idiopathic arthritis

Year:  2015        PMID: 26136885      PMCID: PMC4471688          DOI: 10.3892/etm.2015.2295

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

Review 1.  T-cell and T-cell receptor abnormalities in the immunopathogenesis of juvenile rheumatoid arthritis.

Authors:  A A Grom; R Hirsch
Journal:  Curr Opin Rheumatol       Date:  2000-09       Impact factor: 5.006

2.  Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody.

Authors:  Marta Rodríguez-Palmero; Angels Franch; Margarida Castell; Carme Pelegrí; Francisco J Pérez-Cano; Christoph Kleinschnitz; Guido Stoll; Thomas Hünig; Cristina Castellote
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

Review 3.  Juvenile idiopathic arthritis.

Authors:  Angelo Ravelli; Alberto Martini
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

Review 4.  [Juvenile idiopathic arthritis: from biomarker to treatment].

Authors:  Charlotte M Nusman; J Merlijn van den Berg; Dieneke Schonenberg-Meinema; Mario Maas; Rebecca ten Cate; Taco W Kuijpers
Journal:  Ned Tijdschr Geneeskd       Date:  2013

5.  Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity.

Authors:  A N Vallejo; A R Nestel; M Schirmer; C M Weyand; J J Goronzy
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

Review 6.  Disease of the year: juvenile idiopathic arthritis-associated uveitis--classification and diagnostic approach.

Authors:  Ilknur Tugal-Tutkun; Pierre Quartier; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2014-01-10       Impact factor: 3.070

Review 7.  Prevalence and incidence of juvenile idiopathic arthritis: a systematic review.

Authors:  Sigrid Thierry; Bruno Fautrel; Irène Lemelle; Francis Guillemin
Journal:  Joint Bone Spine       Date:  2013-11-06       Impact factor: 4.929

Review 8.  Costimulation blockade in rheumatic diseases: where we are?

Authors:  Vincent Goëb; Maya H Buch; Edward M Vital; Paul Emery
Journal:  Curr Opin Rheumatol       Date:  2009-05       Impact factor: 5.006

9.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.

Authors:  P S Linsley; J L Greene; W Brady; J Bajorath; J A Ledbetter; R Peach
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

Review 10.  Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.

Authors:  Ofra Goldzweig; Philip J Hashkes
Journal:  Drug Des Devel Ther       Date:  2011-01-26       Impact factor: 4.162

View more
  4 in total

1.  Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.

Authors:  Zu-Liang Deng; Ding-Zhong Zhou; Su-Juan Cao; Qing Li; Jian-Fang Zhang; Hui Xie
Journal:  Inflammation       Date:  2022-03-23       Impact factor: 4.092

Review 2.  Arthritis in children with LRBA deficiency - case report and literature review.

Authors:  Rotem Semo Oz; Melissa S Tesher
Journal:  Pediatr Rheumatol Online J       Date:  2019-12-17       Impact factor: 3.054

Review 3.  The Multi-Omics Architecture of Juvenile Idiopathic Arthritis.

Authors:  Xiaoyuan Hou; Huiqi Qu; Sipeng Zhang; Xiaohui Qi; Hakon Hakonarson; Qianghua Xia; Jin Li
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

4.  Premature Senescence of T-cells Favors Bone Loss During Osteolytic Diseases. A New Concern in the Osteoimmunology Arena.

Authors:  Luis González-Osuna; Alfredo Sierra-Cristancho; Carolina Rojas; Emilio A Cafferata; Samanta Melgar-Rodríguez; Angélica M Cárdenas; Rolando Vernal
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.